Gypsyamber D'Souza1, Devasena Anantharaman2, Tarik Gheit3, Behnoush Abedi-Ardekani4, Daniel C Beachler5, David I Conway6, Andrew F Olshan7, Victor Wunsch-Filho8, Tatiana N Toporcov8, Wolfgang Ahrens9, Kathy Wisniewski7, Franco Merletti10, Stefania Boccia11, Eloiza H Tajara12, Jose P Zevallos13, José Eduardo Levi14, Mark C Weissler13, Sylvia Wright15, Ghislaine Scelo2, Angela L Mazul7, Massimo Tommasino3, Gabriella Cadoni16, Paul Brennan2. 1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore MD, USA. 2. Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France. 3. Infections and Cancer Biology Group, International Agency for Research on Cancer, Lyon, France. 4. Genetic Cancer Susceptibility Group, International Agency for Research on Cancer, Lyon, France. 5. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda MD, USA. 6. School of Medicine, Dentistry, and Nursing, University of Glasgow, Glasgow, UK. 7. Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 8. Department of Epidemiology, School of Public Health, Universidade de São Paulo, São Paulo, Brazil. 9. Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany; Institute for Statistics, University Bremen, Bremen, Germany. 10. CeRMS and Department of Medical Sciences, University of Turin, Turin, Italy. 11. Section of Hygiene-Institute of Public Health, Faculty of Medicine, Università Cattolica del Sacro Cuore, Rome, Italy. 12. Department of Molecular Biology, Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, São Paulo, Brazil. 13. Department of Otolaryngology/Head and Neck Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 14. Virology Lab, Tropical Medicine Institute, Universidade de São Paulo, São Paulo, Brazil. 15. Department of Pathology, Queen Elizabeth University Hospital, Glasgow, UK. 16. Head and Neck Surgery Department, Institute of Otorhinolaryngology, Università Cattolica del Sacro Cuore, Fondazione Policlinico “A. Gemelli”, Rome, Italy
Abstract
OBJECTIVES: To explore whether HPV-related biomarkers predict oropharyngeal squamous cell cancer (OPSCC) survival similarly across different global regions, and to explore their prognostic utility among non-oropharyngeal (non-OP) head and neck cancers. METHODS: Data from 1362 head and neck SCC (HNSCC) diagnosed 2002-2011 was used from epidemiologic studies in: Brazil (GENCAPO study, n=388), U.S. (CHANCE study, n=472), and Europe (ARCAGE study, n=502). Tumors were centrally tested for p16INK4a and HPV16 DNA (by PCR). Risk of mortality was examined using Cox proportional hazard models. RESULTS: There were 517 OPSCC and 845 non-OP HNSCC. Cases were primarily male (81%), ever smokers (91%), with median age of 58yearsandmedian follow-up of 3.1years (IQR=1.4-5.9). Among OPSCC, the risk of mortality was significantly lower among 184 HPV-related (i.e., p16+/HPV16+) compared to 333 HPV-unrelated (p16- and/or HPV16-) cases (HR=0.25, 95%CI=0.18-0.34). Mortality was reduced among HPV-related OPSCC cases from the U.S., Europe, and Brazil (each p⩽0.01) and after adjustment, remained significantly reduced (aHR=0.34, 95%CI=0.24-0.49). Among non-OP HNSCC, neither p16 (aHR=0.83, 95%CI=0.60-1.14), HPV16 DNA (aHR=1.20, 95%CI=0.89-1.63), or p16+/HPV16+ (aHR=0.59, 95%CI=0.32-1.08) was a significantly predictor of mortality. When interaction was tested, the effect of HPV16/p16 was significantly different in OPSCC than non-OP HNSCC (p-interaction=0.02). CONCLUSION: HPV-related OPSCCs had similar survival benefits across these three regions. Prognostic utility of HPV among non-OP HNSCC is limited so tumor HPV/p16 testing should not be routinely done among non-OP HNSCC.
OBJECTIVES: To explore whether HPV-related biomarkers predict oropharyngeal squamous cell cancer (OPSCC) survival similarly across different global regions, and to explore their prognostic utility among non-oropharyngeal (non-OP) head and neck cancers. METHODS: Data from 1362 head and neck SCC (HNSCC) diagnosed 2002-2011 was used from epidemiologic studies in: Brazil (GENCAPO study, n=388), U.S. (CHANCE study, n=472), and Europe (ARCAGE study, n=502). Tumors were centrally tested for p16INK4a and HPV16 DNA (by PCR). Risk of mortality was examined using Cox proportional hazard models. RESULTS: There were 517 OPSCC and 845 non-OP HNSCC. Cases were primarily male (81%), ever smokers (91%), with median age of 58yearsandmedian follow-up of 3.1years (IQR=1.4-5.9). Among OPSCC, the risk of mortality was significantly lower among 184 HPV-related (i.e., p16+/HPV16+) compared to 333 HPV-unrelated (p16- and/or HPV16-) cases (HR=0.25, 95%CI=0.18-0.34). Mortality was reduced among HPV-related OPSCC cases from the U.S., Europe, and Brazil (each p⩽0.01) and after adjustment, remained significantly reduced (aHR=0.34, 95%CI=0.24-0.49). Among non-OP HNSCC, neither p16 (aHR=0.83, 95%CI=0.60-1.14), HPV16 DNA (aHR=1.20, 95%CI=0.89-1.63), or p16+/HPV16+ (aHR=0.59, 95%CI=0.32-1.08) was a significantly predictor of mortality. When interaction was tested, the effect of HPV16/p16 was significantly different in OPSCC than non-OP HNSCC (p-interaction=0.02). CONCLUSION:HPV-related OPSCCs had similar survival benefits across these three regions. Prognostic utility of HPV among non-OP HNSCC is limited so tumor HPV/p16 testing should not be routinely done among non-OP HNSCC.
Authors: Markus Schmitt; I G Bravo; Peter J F Snijders; Lutz Gissmann; Michael Pawlita; Tim Waterboer Journal: J Clin Microbiol Date: 2006-02 Impact factor: 5.948
Authors: Arya Amini; Jagar Jasem; Bernard L Jones; Tyler P Robin; Jessica D McDermott; Shilpa Bhatia; David Raben; Antonio Jimeno; Daniel W Bowles; Sana D Karam Journal: Oral Oncol Date: 2016-03-12 Impact factor: 5.337
Authors: Pagona Lagiou; Christina Georgila; Ploumitsa Minaki; Wolfgang Ahrens; Hermann Pohlabeln; Simone Benhamou; Christine Bouchardy; Alena Slamova; Miriam Schejbalova; Franco Merletti; Lorenzo Richiardi; Kristina Kjaerheim; Antonio Agudo; Xavier Castellsague; Tatiana V Macfarlane; Gary J Macfarlane; Renato Talamini; Luigi Barzan; Cristina Canova; Lorenzo Simonato; Ray Lowry; David I Conway; Patricia A McKinney; Ariana Znaor; Bernard E McCartan; Claire Healy; Mari Nelis; Andres Metspalu; Manuela Marron; Mia Hashibe; Paul J Brennan Journal: Eur J Cancer Prev Date: 2009-02 Impact factor: 2.497
Authors: Rossana Verónica Mendoza López; José Eduardo Levi; José Eluf-Neto; Rosalina Jorge Koifman; Sergio Koifman; Maria Paula Curado; Pedro Michaluart-Junior; David Livingstone Alves Figueiredo; Fabiano Pinto Saggioro; Marcos Brasilino de Carvalho; Luiz Paulo Kowalski; Márcio Abrahão; Francisco de Góis-Filho; Eloiza Helena Tajara; Tim Waterboer; Paolo Boffetta; Paul Brennan; Victor Wünsch-Filho Journal: Cancer Causes Control Date: 2014-01-29 Impact factor: 2.506
Authors: R J Young; D Urban; C Angel; J Corry; B Lyons; N Vallance; S Kleid; T A Iseli; B Solomon; D Rischin Journal: Br J Cancer Date: 2015-03-17 Impact factor: 7.640
Authors: Mererid Evans; Robert Newcombe; Alison Fiander; James Powell; Martin Rolles; Selvam Thavaraj; Max Robinson; Ned Powell Journal: BMC Cancer Date: 2013-05-01 Impact factor: 4.430
Authors: Huaising C Ko; Paul M Harari; Ryan M Sacotte; Shuai Chen; Aaron M Wieland; Menggang Yu; Andrew M Baschnagel; Justine Y Bruce; Randall J Kimple; Matthew E Witek Journal: J Cancer Res Clin Oncol Date: 2017-07-27 Impact factor: 4.553
Authors: Sibo Tian; Jeffrey M Switchenko; Jaymin Jhaveri; Richard J Cassidy; Matthew J Ferris; Robert H Press; Neil T Pfister; Mihir R Patel; Nabil F Saba; Mark W McDonald; Kristin A Higgins; David S Yu; Walter J Curran; Theresa W Gillespie; Jonathan J Beitler Journal: Cancer Date: 2019-04-23 Impact factor: 6.860
Authors: Laura Martin-Gomez; William J Fulp; Michael J Schell; Bradley Sirak; Martha Abrahamsen; Kimberly A Isaacs-Soriano; Attila Lorincz; Bruce Wenig; Christine H Chung; Jimmy J Caudell; Anna R Giuliano Journal: Oral Oncol Date: 2019-04-03 Impact factor: 5.337
Authors: Siddharth Sheth; Douglas R Farquhar; Nicholas R Lenze; Angela Mazul; Paul Brennan; Devasena Anantharaman; Behnoush Abedi-Ardekani; Jose P Zevallos; D Neil Hayes; F Olshan Journal: Am J Otolaryngol Date: 2020-10-22 Impact factor: 1.808
Authors: Paolo Boscolo-Rizzo; Manuel Zorzi; Annarosa Del Mistro; Maria Cristina Da Mosto; Giancarlo Tirelli; Carlotta Buzzoni; Massimo Rugge; Jerry Polesel; Stefano Guzzinati Journal: PLoS One Date: 2018-02-07 Impact factor: 3.240
Authors: Anna Janecka-Widła; Anna Mucha-Małecka; Kaja Majchrzyk; Krzysztof Halaszka; Marcin Przewoźnik; Dorota Słonina; Beata Biesaga Journal: J Cancer Res Clin Oncol Date: 2020-05-05 Impact factor: 4.553